Owsley J, Jimeno A, Diamond J R
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528.
Maintaining cell-cycle control has become a mainstay in treatment for many cancers. Cell-cycle manipulation can be especially valuable in breast cancer tumor cells that will often express hormone receptors that are amenable to anti-hormone receptor-targeted therapies. Despite these treatments, patients often progress, leading to other targeted agents being investigated to help promote progression-free survival. Cyclin-dependent kinases (CDKs) have been identified as contributors in the process of cell division. Combining inhibitors of CDKs with traditional endocrine treatments has shown significant progression-free survival in patients with metastatic breast cancer. One such CDK inhibitor, palbociclib, has shown great promise in the treatment of hormone receptor-positive breast cancer. In this article we review the traditional hormonal treatments of breast cancer, how CDK inhibition is beneficial in the treatment of this disease, and the preclinical and clinical data supporting the use of this medication.
维持细胞周期调控已成为许多癌症治疗的主要手段。细胞周期操控在乳腺癌肿瘤细胞中可能特别有价值，这些细胞通常会表达适合抗激素受体靶向治疗的激素受体。尽管有这些治疗方法，但患者仍常出现病情进展，这促使人们研究其他靶向药物以帮助提高无进展生存期。细胞周期蛋白依赖性激酶（CDKs）已被确定为细胞分裂过程中的促成因素。将CDK抑制剂与传统内分泌治疗相结合，已在转移性乳腺癌患者中显示出显著的无进展生存期。一种这样的CDK抑制剂，即哌柏西利，在激素受体阳性乳腺癌的治疗中显示出巨大潜力。在本文中，我们回顾了乳腺癌的传统激素治疗方法、CDK抑制在该疾病治疗中的益处，以及支持使用这种药物的临床前和临床数据。
